ImageneBio
ImageneBio's revenue fell 77.1% to $1 million in fiscal 2025. Its operating margin was −6,056.4%, down from −1,057.1% a year earlier. The diluted share count rose 303.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
ImageneBio lost money in fiscal 2025: a net loss of $45 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 232 | 157 | 176 | 12 | 135 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 8.7x | 7.4x | 12.6x | 0.7x | 12.5x |
| Quick ratio | 8.7x | 7.4x | 12.6x | 0.7x | 12.5x |
Cash flow
Projections
Project ImageneBio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $95,840 of ImageneBio shares on the open market, and 1 insider sold $17,334.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Robert B LallyPrincipal Accounting Officer | Sold | 1,525 | $5.34 | $8,144 | Form 4 |
| Jul 16, 2026 | Robert B LallyPrincipal Accounting Officer | Sold | 1,671 | $5.50 | $9,190 | Form 4 |
| Dec 24, 2025 | Joseph P SlatteryDirector | Bought | 16,000 | $5.99 | $95,840 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −916.4% | — | — |
| Altman Z'' | −7.74 | −64.07 | 5.55 |
| Accruals ratio | 6.3% | −14.7% | 3.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Fail | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | — |
Compare
Put ImageneBio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ImageneBio | FY25 | −77.1% | −6,056.4% | — | — | — | — | |
| ProKidney | FY25 | 1,075.0% | −18,477.8% | −15,152.6% | — | — | — | Compare |
| Rallybio | FY25 | 34.9% | −3,853.6% | — | — | — | — | Compare |
| Pluri | FY26 | −23.9% | −2,454.5% | −1,990.3% | — | — | — | Compare |
| Shattuck Labs | FY25 | −82.5% | −5,150.8% | −3,995.3% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 9 | 31 | 16 | 9 | 4 | 1 |
| Revenue growth | — | 237.0% | −49.6% | −41.4% | −61.8% | −77.1% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 45 | 47 | 64 | 60 | 32 | 28 |
| Operating income | −44 | −34 | −71 | −75 | −37 | −48 |
| Net income | −44 | −34 | −69 | −68 | −37 | −45 |
| Diluted EPS (US$) | −640.00 | −48.80 | −76.00 | −65.20 | — | −9.64 |
| Diluted shares (millions) | 0 | 1 | 1 | 1 | 1 | 5 |
| Cash flow | ||||||
| Cash from operations | −38 | −60 | −74 | −80 | −21 | −48 |
| Capital expenditure | 1 | 2 | 1 | 0 | — | — |
| Free cash flow | −39 | −62 | −76 | −80 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 1 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 5 | 8 | 8 | 0 | 15 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 162 | 232 | 157 | 176 | 12 | 135 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 168 | 248 | 172 | 192 | 16 | 153 |
| Total liabilities | 64 | 40 | 25 | 22 | 17 | 20 |
| Shareholders' equity | −101 | 208 | 147 | −126 | −161 | 133 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −484.2% | −110.2% | −454.0% | −823.3% | −1,057.1% | −6,056.4% |
| Net margin | −481.4% | −110.1% | −440.3% | −744.2% | −1,044.8% | −5,668.6% |
| Free cash flow margin | −419.8% | −200.1% | −483.7% | −875.1% | — | — |
| Rule of 40 (growth + FCF margin) | — | 36.9% | −533.3% | −916.4% | — | — |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −63.9% | −38.8% | −653.5% | — | — |
| Return on assets | — | −16.4% | −32.7% | −37.4% | −35.2% | −53.7% |
| Net debt to EBITDA | — | — | — | — | — | — |